Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
Figure 3
Metnase levels predict breast cancer cell sensitivity to Topo IIα inhibitors.
Cells stably transfected with vector control, or Metnase shRNA were treated with VP-16 (A) or adriamycin (B) and colony survival was measured as described. Values are averages ±SEM for three determinations. (C) Cells transfected with control (shGFP) or Metnase shRNA were treated with 1 µM adriamycin for 24 hrs and apoptosis (annexin-V) and cell death (propidium iodide) were analyzed by FACS. Values are averages (+SEM) for three determinations.
